Suppression of Hedgehog signalling promotes pro-tumourigenic integrin expression and function

Journal of Pathology

Volumn 233, Issue 2, 2014, Pages 196-208

  Moutasim, Karwan A ^a   Mellows, Toby ^a   Mellone, Massimiliano ^a   Lopez, Marie Antoinette ^a   Tod, Joanne ^a   Kiely, Philip C ^a   Sapienza, Karen ^b   Greco, Azzura ^c   Neill, Graham W ^b   Violette, Shelia ^d   Weinreb, Paul H ^d   Marshall, John F ^b   Ottensmeier, Christian H ^a,e   Sayan, A Emre ^a   Jenei, Veronika ^a   Thomas, Gareth J ^a,e  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c INSTITUTE OF HEPATOLOGY   (United Kingdom)

^d BIOGEN   (United States)

^e Southampton NIHR Biomedical Research Unit in Nutrition Diet and Lifestyle   (United Kingdom)

Author keywords

cancer; Hedgehog; integrin; invasion; stroma

Indexed keywords

ALPHAVBETA6 INTEGRIN; INTEGRIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1; TRANSFORMING GROWTH FACTOR BETA1; VISMODEGIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL CELL CARCINOMA; CANCER CELL; CANCER PATIENT; CARCINOGENICITY; CELL DIFFERENTIATION; CELL FUNCTION; CELL IMMORTALIZATION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; EMBRYO; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; GENE TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; MOUSE; MYOFIBROBLAST; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR CELL;

CANCER; HEDGEHOG; INTEGRIN; INVASION; STROMA;

ANTIGENS, NEOPLASM; CARCINOMA, BASAL CELL; CELL LINE; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; COCULTURE TECHNIQUES; DOWN-REGULATION; FIBROBLASTS; HEDGEHOG PROTEINS; HUMANS; INTEGRINS; KERATINOCYTES; PANCREATIC NEOPLASMS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSCRIPTION FACTORS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84900824079     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4342     Document Type: Article

References (85)

1. Briscoe J, Thérond PP,. The mechanisms of Hedgehog signalling and its roles in development and disease. Nature Rev Mol Cell Biol 2013; 14: 416-429.
2. Ghali L, Wong ST, Green J, et al., Gli1 protein is expressed in basal cell carcinomas, outer root sheath keratinocytes and a subpopulation of mesenchymal cells in normal human skin. J Invest Dermatol 1999; 113: 595-599.
3. Thayer SP, di Magliano MP, Heiser PW, et al., Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003; 425: 851-856.
4. Dey J, Ditzler S, Knoblaugh SE, et al., A distinct Smoothened mutation causes severe cerebellar developmental defects and medulloblastoma in a novel transgenic mouse model. Mol Cell Biol 2012; 32: 4103-4115.
5. Ingham PW, Nystedt S, Nakano Y, et al., Patched represses the Hedgehog signalling pathway by promoting modification of the Smoothened protein. Curr Biol 2000; 10: 1315-1318.
6. Sasaki H, Nishizaki Y, Hui C, et al., Regulation of Gli2 and Gli3 activities by an amino-terminal repression domain: implication of Gli2 and Gli3 as primary mediators of Shh signalling. Development 1999; 126: 3915-3924.
7. Stecca B, Ruiz IAA,. Context-dependent regulation of the GLI code in cancer by Hedgehog and non-Hedgehog signals. J Mol Cell Biol 2010; 2: 84-95.
8. Regl G, Neill GW, Eichberger T, et al., Human GLI2 and GLI1 are part of a positive feedback mechanism in basal cell carcinoma. Oncogene 2002; 21: 5529-5539.
9. Hahn H, Wicking C, Zaphiropoulous PG, et al., Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996; 85: 841-851.
10. Johnson RL, Rothman AL, Xie J, et al., Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996; 272: 1668-1671.
11. Xie J, Murone M, Luoh SM, et al., Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998; 391: 90-92.
12. Adolphe C, Hetherington R, Ellis T, et al., Patched1 functions as a gatekeeper by promoting cell cycle progression. Cancer Res 2006; 66: 2081-2088.
13. Oro AE, Higgins KM, Hu Z, et al., Basal cell carcinomas in mice overexpressing Sonic hedgehog. Science 1997; 276: 817-821.
14. Grachtchouk M, Mo R, Yu S, et al., Basal cell carcinomas in mice overexpressing Gli2 in skin. Nature Genet 2000; 24: 216-217.
15. Nilsson M, Unden AB, Krause D, et al., Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. Proc Natl Acad Sci U S A 2000; 97: 3438-3443.
16. McMillan R, Matsui W,. Molecular pathways: the Hedgehog signalling pathway in cancer. Clin Cancer Res 2012; 18: 4883-4888.
17. Axelson M, Liu K, Jiang X, et al., U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced or metastatic basal cell carcinoma. Clin Cancer Res 2013; 19: 2289-2293.
18. Chang AL, Oro AE,. Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma. Arch Dermatol 2012; 148: 1324-1325.
19. Aasi S, Silkiss R, Tang JY, et al., New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases. JAMA Dermatol 2013; 149: 242-243.
20. Ally MS, Wysong A, Tang JY, et al., Comment on basal cell carcinoma rebound after cessation of vismodegib in an individual with basal cell nevus syndrome. Dermatol Surg 2013; 39: 1413-1414.
21. Iarrobino A, Messina JL, Kudchadkar R, et al., Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib. J Am Acad Dermatol 2013; 69: e33-e34.
22. LoRusso PM, Rudin CM, Reddy JC, et al., Phase I trial of Hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011; 17: 2502-2511.
23. Sekulic A, Migden MR, Oro AE, et al., Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012; 366: 2171-2179.
24. Thomas GJ, Nyström ML, Marshall JF,. αvβ6 integrin in wound healing and cancer of the oral cavity. J Oral Pathol Med 2006; 35: 1-10.
25. 6 inhibits tumor progression in vivo by a transforming growth factor-β-regulated mechanism. Cancer Res 2008; 68: 561-570.
26. Sipos B, Hahn D, Carceller A, et al., Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology 2004; 45: 226-236.
27. Hazelbag S, Kenter GG, Gorter A, et al., Overexpression of the αvβ6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J Pathol 2007; 212: 316-324.
28. Bates RC, Bellovin DI, Brown C, et al., Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 2005; 115: 339-347.
29. Li X, Yang Y, Hu Y, et al., Alphavbeta6-Fyn signalling promotes oral cancer progression. J Biol Chem 2003; 278: 41646-41653.
30. Singh A, Greninger P, Rhodes D, et al., A gene expression signature associated with 'K-Ras addiction' reveals regulators of EMT and tumor cell survival. Cancer Cell 2009; 15: 489-500.
31. Nystrom ML, McCulloch D, Weinreb PH, et al., Cyclooxygenase-2 inhibition suppresses αvβ6 integrin-dependent oral squamous carcinoma invasion. Cancer Res 2006; 66: 10833-10842.
32. Yap LF, Jenei V, Robinson CM, et al., Upregulation of Eps8 in oral squamous cell carcinoma promotes cell migration and invasion through integrin-dependent Rac1 activation. Oncogene 2009; 28: 2524-2534.
33. Munger JS, Huang X, Kawakatsu H, et al., The integrin αvβ6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999; 96: 319-328.
34. Moutasim KA, Jenei V, Sapienza K, et al., Betel-derived alkaloid up-regulates keratinocyte αvβ6 integrin expression and promotes oral submucous fibrosis. J Pathol 2011; 223: 366-377.
35. Marsh D, Suchak K, Moutasim KA, et al., Stromal features are predictive of disease mortality in oral cancer patients. J Pathol 2011; 223: 470-481.
36. Marsh D, Dickinson S, Neill GW, et al., αvβ6 integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation. Cancer Res 2008; 68: 3295-3303.
37. Lauth M, Bergstrom A, Shimokawa T, et al., Inhibition of Gli-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A 2007; 104: 8455-8460.
38. Sayan AE, Griffiths TR, Pal R, et al., SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. Proc Natl Acad Sci U S A 2009; 106: 14884-14889.
39. Di Cara D, Rapisarda C, Sutcliffe JL, et al., Structure-function analysis of Arg-Gly-Asp helix motifs in αvβ6 integrin ligands. J Biol Chem 2007; 282: 9657-9665.
40. Thomas GJ, Lewis MP, Whawell SA, et al., Expression of the αvβ6 integrin promotes migration and invasion in squamous carcinoma cells. J Invest Dermatol 2001; 117: 67-73.
41. Abe M, Harpel JG, Metz CN, et al., An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem 1994; 216: 276-284.
42. Nyström ML, Thomas GJ, Stone M, et al., Development of a quantitative method to analyse tumour cell invasion in organotypic culture. J Pathol 2005; 205: 468-475.
43. Oro AE, Higgins K,. Hair cycle regulation of Hedgehog signal reception. Dev Biol 2003; 255: 238-248.
44. Dahmane N, Lee J, Robins P, et al., Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours. Nature 1997; 389: 876-881.
45. Neill GW, Harrison WJ, Ikram MS, et al., GLI1 repression of ERK activity correlates with colony formation and impaired migration in human epidermal keratinocytes. Carcinogenesis 2008; 29: 738-746.
46. Ramos DM, Dang D, Sadler S,. The role of the integrin alpha v beta6 in regulating the epithelial to mesenchymal transition in oral cancer. Anticancer Res 2009; 29: 125-130.
47. Erkan M, Michalski CW, Rieder S, et al., The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol 2008; 6: 1155-1161.
48. De Wever O, Demetter P, Mareel M, et al., Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 2008; 123: 2229-2238.
49. Zambruno G, Marchisio PC, Marconi A, et al., Transforming growth factor-beta 1 modulates beta 1 and beta 5 integrin receptors and induces the de novo expression of the alpha v beta 6 heterodimer in normal human keratinocytes: implications for wound healing. J Cell Biol 1995; 129: 853-865.
50. Sullivan BP, Weinreb PH, Violette SM, et al., The coagulation system contributes to αVβ6 integrin expression and liver fibrosis induced by cholestasis. Am J Pathol 2010; 177: 2837-2849.
51. Sullivan BP, Kassel KM, Manley S, et al., Regulation of transforming growth factor-β1-dependent integrin β6 expression by p38 mitogen-activated protein kinase in bile duct epithelial cells. J Pharmacol Exp Ther 2011; 337: 471-478.
52. Moustakas A, Souchelnytskyi S, Heldin C-H,. Smad regulation of TGF-β signal transduction. J Cell Sci 2001; 114: 4359-4369.
53. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al., Inhibiting the Hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012; 366: 2180-2188.
54. Christenson LJ, Borrowman TA, Vachon CM, et al., Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. J Am Med Assoc 2005; 294: 681-690.
55. Walling HW, Fosko SW, Geraminejad PA, et al., Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev 2004; 23: 389-402.
56. Zhao R, Liu XQ, Wu XP, et al., Vascular endothelial growth factor (VEGF) enhances gastric carcinoma invasiveness via integrin alpha(v)beta6. Cancer Lett 2010; 287: 150-156.
57. Nam JS, Terabe M, Kang MJ, et al., Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 2008; 68: 3915-3923.
58. Hausner SH, Kukis DL, Gagnon MK, et al., Evaluation of [64Cu]Cu-DOTA and [64Cu]Cu-CB-TE2A chelates for targeted positron emission tomography with an alphavbeta6-specific peptide. Mol Imaging 2009; 8: 111-121.
59. Saha A, Ellison D, Thomas GJ, et al., High-resolution in vivo imaging of breast cancer by targeting the pro-invasive integrin alphavbeta6. J Pathol 2010; 222: 52-63.
60. Coughlan L, Vallath S, Saha A, et al., In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery. J Virol 2009; 83: 6416-6428.
61. Hezel AF, Deshpande V, Zimmerman SM, et al., TGF-β and αvβ6 integrin act in a common pathway to suppress pancreatic cancer progression. Cancer Res 2012; 72: 4840-4845.
62. Niu J, Gu X, Ahmed N, et al., The alphaVbeta6 integrin regulates its own expression with cell crowding: implications for tumour progression. Int J Cancer 2001; 92: 40-48.
63. Scott KA, Arnott CH, Robinson SC, et al., TNF-alpha regulates epithelial expression of MMP-9 and integrin alphavbeta6 during tumour promotion. A role for TNF-alpha in keratinocyte migration? Oncogene 2004; 23: 6954-6966.
64. Levy L, Hill CS,. Smad4 dependency defines two classes of transforming growth factor β (TGF-β) target genes and distinguishes TGF-β-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol Cell Biol 2005; 25: 8108-8125.
65. Tatler AL, Saini G, Goodwin A, et al., S69 transcriptional mechanisms regulating expression of the Avb6 integrin in IPF. Thorax 2012; 67: A34-A35.
66. Gao J, Khan AA, Shimokawa T, et al., A feedback regulation between Kindlin-2 and GLI1 in prostate cancer cells. FEBS Lett 2013; 587: 631-638.
67. Kinzler KW, Vogelstein B,. The GLI gene encodes a nuclear protein which binds specific sequences in the human genome. Mol Cell Biol 1990; 10: 634-642.
68. Wei X, Xia Y, Li F, et al., Kindlin-2 mediates activation of TGF-β/Smad signalling and renal fibrosis. J Am Soc Nephrol 2013; 24: 1387-1398.
69. Yoon JW, Kita Y, Frank DJ, et al., Gene expression profiling leads to identification of GLI1-binding elements in target genes and a role for multiple downstream pathways in GLI1-induced cell transformation. J Biol Chem 2002; 277: 5548-5555.
70. Choi S-J, Moon JH, Ahn YW, et al., Tsc-22 enhances TGF-beta signalling by associating with Smad4 and induces erythroid cell differentiation. Mol Cell Biochem 2005; 271: 23-28.
71. Yan X, Zhang J, Pan L, et al., TSC-22 promotes transforming growth factor β-mediated cardiac myofibroblast differentiation by antagonizing Smad7 activity. Mol Cell Biol 2011; 31: 3700-3709.
72. Kleeff J, Ishiwata T, Maruyama H, et al., The TGF-beta signalling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 1999; 18: 5363-5372.
73. Gambichler T, Skrygan M, Kaczmarczyk JM, et al., Increased expression of TGF-beta/Smad proteins in basal cell carcinoma. Eur J Med Res 2007; 12: 509-514.
74. Ohta H, Aoyagi K, Fukaya M, et al., Cross talk between hedgehog and epithelial-mesenchymal transition pathways in gastric pit cells and in diffuse-type gastric cancers. Br J Cancer 2009; 100: 389-398.
75. Kaye SB, Fehrenbacher L, Holloway R, et al., A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission. Clin Cancer Res 2012; 18: 6509-6518.
76. Ji Z, Mei FC, Xie J, et al., Oncogenic KRAS activates Hedgehog signalling pathway in pancreatic cancer cells. J Biol Chem 2007; 282: 14048-14055.
77. Nolan-Stevaux O, Lau J, Truitt ML, et al., GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev 2009; 23: 24-36.
78. Wang Y, Ding Q, Yen CJ, et al., The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell 2012; 21: 374-387.
79. Zwerner JP, Joo J, Warner KL, et al., The EWS/FLI1 oncogenic transcription factor deregulates Gli1. Oncogene 2008; 27: 3282-3291.
80. Dijkgraaf GJ, Alicke B, Weinmann L, et al., Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res 2011; 71: 435-444.
81. Fukuchi M, Masuda N, Miyazaki T, et al., Decreased Smad4 expression in the transforming growth factor-beta signaling pathway during progression of esophageal squamous cell carcinoma. Cancer 2002; 95: 737-743.
82. Korc M., Smad4: gatekeeper gene in head and neck squamous cell carcinoma. J Clin Invest 2009; 119: 3208-3211.
83. Iacobuzio-Donahue CA, Wilentz RE, Argani P, et al., Dpc4 protein in mucinous cystic neoplasms of the pancreas: frequent loss of expression in invasive carcinomas suggests a role in genetic progression. Am J Surg Pathol 2000; 24: 1544-1548.
84. Ding Z, Wu CJ, Chu GC, et al., SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011; 470: 269-273.
85. Yang L, Mao C, Teng Y, et al., Targeted disruption of Smad4 in mouse epidermis results in failure of hair follicle cycling and formation of skin tumors. Cancer Res 2005; 65: 8671-8678.